Goodwin’s Mergers and Acquisitions team advised Centerview Partners as exclusive financial advisor to Kite Pharma, Inc. in Kite’s definitive agreement to be acquired by Gilead Sciences for $180.00 per share in cash. The transaction, which values Kite at approximately $11.9 billion, was unanimously approved by both Kite and Gilead’s Boards of Directors and is anticipated to close in the fourth quarter of 2017. The transaction will provide opportunities for diversification of revenues, and is expected to be neutral to earnings by year three and accretive thereafter.
Kite is a biopharmaceutical company engaged in the development of innovative cancer immunotherapies with a goal of providing rapid, long-term, durable response and eliminating the burden of chronic care.
Centerview Partners is a leading independent investment banking and advisory firm. The firm provides advice on mergers and acquisitions, financial restructurings, valuation, and capital structure to companies, institutions and governments.
For additional details on the transaction, please read the press release.